AbbVie Strengthens Immunology Leadership with $10.9 Billion Apogee Therapeutics Acquisition – Meet them this November

Talawar Therapeutics Heads to Nasdaq via SPAC Deal to Bankroll Eczema Asset

10 Clinical Trials to Watch Out for in the latter half of 2026 – Read here

Akero execs reunite to advance long-acting psoriasis pill

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test

Sanofi halts development of troubled immune drug in eczema

From 140 Million Cells to Human Trials: Applying AI & Human Tissue Biology to Accelerate Dermatology Drug Discovery

3:45 pm - Wednesday 4th November 2026

Building proprietary cellular atlases through advanced multi-omics approaches to reveal novel disease mechanisms and therapeutic opportunities
Leveraging AI and machine learning to identify, prioritize and validate targets emerging from complex human biology datasets
Sharing lessons from advancing an AI-discovered therapeutic from target identification to clinical studies in approximately half the traditional development timeline

Frederick Beddingfield

Chief Executive Officer & Director

Rubedo Life Sciences